Domain: medical diagnostics (in vitro diagnostics & devices) – rapid tests, CRISPR-based rapid molecular tools for diseases (new strains/next clade)
Founded by IITB alumni, Ostic focuses on the manufacturing and marketing of in-vitro diagnostics (IVD), developing novel innovations for high-burden diseases and future pandemics, and providing R&D solutions and manufacturing services in the IVD sector. The company collaborates with various institutions on several health issues. They work on Tuberculosis and Paragonimiasis with the Federal Health Institute, Fiocruz, Brazil, and NIST, Nagaland. For neglected tropical diseases—Leptospirosis, Filariasis, and Leishmaniasis—collaborators include Fiocruz, Brazil; Ohio State Global One Health, LLC; and Addis Ababa, Ethiopia. Vector-borne diseases (Malaria, Dengue, Chikungunya, and Zika Virus) are addressed in collaboration with the Federal Health Institute, Fiocruz, Brazil. They also work on Monkeypox, Zika Virus, and Swine Flu with NIV, Pune (ICMR); Cervical Cancer with NIST, Nagaland; Sickle Cell Anemia with KIIT, Bhubaneswar; and a device for detecting soil-transmitted Helminth infections with GTU, Gujarat. Additionally, they are developing rapid molecular and CRISPR-based diagnostics for resistant strains with the University of Florida, USA.
The company has secured several grants and investments, including: DST-CAWACH Grant Cum Loan (2020) for $178,692 USD; DST SEED funds for Rapid TB Tests (2019) for $23,825 USD; Nidhi 4.0 Covid 2.0 Grant Cum Loan (2021) for $41,694 USD; Covid Ignition Grant (2020) for $59,564 USD with the University of Florida (USISTEF); BRICS Grant (Brazil) 2023 for $28,652 USD; and Institute of Eminence Funds of IIT Bombay (July 2024) for $50,306 USD. A BIRAC, ETA Grant for Sickle Cell Anemia Diagnostics ($100K USD) is yet to be released (August 2024). The company currently has 10 products on the market (8 Rapid Diagnostic Tests and 2 Nutraceuticals) and over 460 customers, including ISRO Hospital, Military Hospitals, AIIMS, ESIC Hospitals, and IIT Roorkee, primarily through the GEM Portal.
The company holds registered trademarks for a variety of rapid diagnostic tests (RDTs), including those for COVID-19 (Cov Ant ®), neglected tropical diseases (OstidetectNT ®), sickle cell anemia (OstisickleScan ®), vector-borne diseases (OstidetectVD ®), and tuberculosis (OstidetectTB ®), along with other brands (Ostic Pharma ®, Ostic ®, Ostisterone ®). They also have filed patents for RDTs targeting neglected tropical diseases, sickle cell anemia, a one-step tuberculosis antigen detection test, and a one-step rapid combo test for vector-borne diseases.
Emerging Startup Award (VOH) - January 2025. ASEAN India Scale Hub Program, Indonesia - 2024 (IITK & DST). Selected as Finalists - Asian Entrepreneurship Award, Japan (2023). Startup Award (India-UK International Conference, 2022), Kashmir. SARTHI Award - Bill & Melinda Gates Foundation, FICCI & ADPC, 2022 (Indonesia). Runner up - Global Innovation Forum, Japan (GIF 2022).
The team possesses diverse expertise, spanning technical backgrounds in Pharma, Biotech, Chemical Engineering, and Biomedical Engineering from IIT Bombay, complemented by experience in QA, QC, manufacturing for medical diagnostics and devices (as per CDSCO regulations), market research, and business development.
MD and CEO
Technical Director
Clinical Advisor - Former Head, Healthcare Laboratory & Research Centre Naga Hospital Kohima Founder, Naga Institute of Science & Technology, Kohima, Nagaland
Advisor- Microbiology & field testing
Advisor - Clinical validation
QC in Rapid and Molecular biology
3D Printer, developing devices, Instruments and Biological equipments and Software development
Mentor for Business Development
Consultant & Mentor
Advisor for QC and Validation
